Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $21.8 million.

  • NewAmsterdam Pharma's Gains from Investment Securities rose 788.76% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 788.76%. This contributed to the annual value of $19.0 million for FY2024, which is 2056.29% up from last year.
  • Per NewAmsterdam Pharma's latest filing, its Gains from Investment Securities stood at $21.8 million for Q3 2025, which was up 788.76% from $22.2 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Gains from Investment Securities ranged from a high of $22.2 million in Q2 2025 and a low of $1.6 million during Q3 2023
  • Over the past 4 years, NewAmsterdam Pharma's median Gains from Investment Securities value was $19.8 million (recorded in 2024), while the average stood at $17.4 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma's Gains from Investment Securities surged by 116130.96% in 2024, and later skyrocketed by 788.76% in 2025.
  • NewAmsterdam Pharma's Gains from Investment Securities (Quarter) stood at $11.4 million in 2022, then tumbled by 85.93% to $1.6 million in 2023, then soared by 1056.25% to $18.5 million in 2024, then grew by 17.69% to $21.8 million in 2025.
  • Its last three reported values are $21.8 million in Q3 2025, $22.2 million for Q2 2025, and $21.9 million during Q1 2025.